Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New radioactive drug targets Hard-to-Treat prostate cancer

NCT ID NCT07363486

First seen Jan 24, 2026 · Last updated May 19, 2026 · Updated 15 times

Summary

This study tests a new drug called 225Ac-LNC1011 for men with a type of advanced prostate cancer that no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells using a special targeting molecule. The goal is to find the safest and most effective dose, and to see if it can shrink tumors or slow the disease. Only 9 participants will be enrolled in this early-phase trial.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350005, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.